Видео ютуба по тегу Speaker: Joaquim Bellmunt

Prof Joaquim Bellmunt
Prof Joaquim Bellmunt
Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer
Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer
Bladder cancer: chemotherapy vs. immunotherapy
Bladder cancer: chemotherapy vs. immunotherapy
Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer
Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer
Maintenance therapy for bladder cancer
Maintenance therapy for bladder cancer
Sequencing and treatment strategies in advanced urothelial carcinoma
Sequencing and treatment strategies in advanced urothelial carcinoma
Long term outcomes in JAVELIN Bladder 100: avelumab in urothelial carcinoma
Long term outcomes in JAVELIN Bladder 100: avelumab in urothelial carcinoma
Dr. Bellmunt on PD-L1 Data in Bladder Cancer
Dr. Bellmunt on PD-L1 Data in Bladder Cancer
IMvigor010 & IMvigor011: ctDNA as a response biomarker for adjuvant atezolizumab in high-risk MIBC
IMvigor010 & IMvigor011: ctDNA as a response biomarker for adjuvant atezolizumab in high-risk MIBC
Perioperative treatment strategies for high-risk bladder cancer
Perioperative treatment strategies for high-risk bladder cancer
Treatment options and their rollout for patients with metastatic urothelial carcinoma
Treatment options and their rollout for patients with metastatic urothelial carcinoma
Current and upcoming clinical trials in bladder cancer
Current and upcoming clinical trials in bladder cancer
How can we improve responses to immunotherapy in patients with bladder cancer?
How can we improve responses to immunotherapy in patients with bladder cancer?
Highlights in bladder cancer at ESMO 2022
Highlights in bladder cancer at ESMO 2022
KEYNOTE-045 – pembrolizumab as second-line treatment in urothelial carcinoma
KEYNOTE-045 – pembrolizumab as second-line treatment in urothelial carcinoma
Highlights in bladder cancer from ASCO 2022
Highlights in bladder cancer from ASCO 2022
Overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
Overview of urothelial carcinoma treatment landscape – the promise of immunotherapy
When can checkpoint inhibitors be used to treat urothelial carcinoma?
When can checkpoint inhibitors be used to treat urothelial carcinoma?